Study on the Change of T-cell Subtype with Pegylated Interferon-α and Ribavirin Combined Therapy in Chronic Hepatitis C Patients

• Main Authors: Shih chiaju, 施佳如
• Other Authors: 葉湘裕
• Format: Others
• Language: zh-TW
• Published: 2016
• Online Access: http://ndltd.ncl.edu.tw/handle/unc2zr

碩士 === 弘光科技大學 === 營養醫學研究所 === 104 === Patients with chronic hepatitis C virus (HCV) infection may progress toward cirrhosis, and liver cancer. A combination of pegylated interferon-α and ribavirin is the standard therapy for chronic HCV infection. However,there are currently no immunological predictive markers for effective treatment response. T cells expressing the CD45RA+marker are considered a naïve subset. Antigenic stimulation converts T cells from CD45RA+ to CD45RO+ (memory subset). CD45RO+ cells produce lymphokine leading to maintenance and up-regulation of immune reactions, ultimately destroying viruses. The present study investigates the CD45RA+/ CD4+CD45RA+ and CD45RO+/CD4+CD45RO+ changes in various response period of chronic HCV patients undergoing the standard treatment. The observed changes of these immunological makers will be used to evaluate the effectiveness of treatment in patients with HCV infection. Thirty-two subjects were followed through a combination treatment with peginterferon αlpha-2a (Pegasys®) and ribavirin (Ribavirin). Subjects with Acute hepatitis HCV, chronic renal failure, hepatitis B virus infection, cirrhosis and cancer were excluded. Serum biochemical makers and immunoly factors including albumin, triglyceride, cholesterol, ALT, AST, creatinine, CBC,CD3+ , CD4+ , CD8+, CD45RA+ , CD4+CD45RA+, CD45RO+and CD4+CD45RO+ were analysed before , during and after treament. Collectively, these data are statistically analyzed. Data were expressed as mean±SD. Significant differences (p<0.05) at every time points were revealed by one-way ANOVA.All calculations were performed with SPSS version 20 (SPSS Inc., Chicago, IL, USA).The proportions of CD45RA+ cells were decreased significantly after 4th , 12th and 24th week treatment, and the proportions of CD45RO+ cells were increased at 24th week during the treatment and post-therapy 4th week treatment (p<0.05). The sustained virological response patients had increased levels of CD45RO+/ CD4+CD45RO+ cells and had decreased levels of CD45RA+/ CD4+CD45RA+. However, the non-sustained virological response patients had decreased levels of CD45RA + / CD4+CD45RA+ cells and CD45RO+ / CD4+CD45RO+ cells. In this study, we observed changes in the proportions of T-cell subtype level, which could be used as an indicator of effictive treatment in patients with chronic HCV infection.